Publications by authors named "J-M Baste"
Article Synopsis
- Non-small cell lung cancer (NSCLC) often leads to compromised lung function, and this study focuses on the effects of surgical methods, specifically minimally invasive surgery (MIS), on 90-day post-operative mortality in high-risk patients.
- The research analyzed data from over 46,000 patients, identifying high-risk individuals with poor lung function, and found a significantly higher mortality rate in this group compared to low-risk patients.
- Results indicated that high-risk patients undergoing MIS had lower mortality rates than those undergoing traditional open surgery, even matching the mortality rates of low-risk patients.
Article Synopsis
- * Immune checkpoint inhibitors and targeted therapies have transformed treatment for NSCLC, offering better outcomes than traditional chemotherapy, although issues with acquired resistance remain.
- * Thoracic surgery has improved through minimally invasive techniques and precision surgery, emphasizing comprehensive patient care from pre-operative support through post-treatment follow-up and potential salvage surgery options.
Background: Nowadays, video-assisted thoracoscopic surgery (VATS) and robotic-assisted thoracoscopic surgery (RATS) are known to be safe and efficient surgical procedures to treat early-stage non-small cell lung cancer (NSCLC). We assessed whether RATS increased disease-free survival (DFS) compared with VATS for lobectomy and segmentectomy.
Methods: This retrospective cohort study included patients treated for resectable NSCLC performed by RATS or VATS, in our tertiary care center from 2012 to 2019.
Background: Immune checkpoint inhibitors (ICIs) are the standard of care for non-resectable non-small-cell lung cancer and are under investigation for resectable disease. Some authors have reported difficulties during lung surgery following ICI treatment. This retrospective study investigated the perioperative outcomes of lung resection in patients with preoperative ICI.
View Article and Find Full Text PDFNon-small cell lung cancers (NSCLC) are different today, due to the increased use of screening programs and of innovative systemic therapies, leading to the diagnosis of earlier and pre-invasive tumors, and of more advanced and controlled metastatic tumors. Surgery for NSCLC remains the cornerstone treatment when it can be performed. The role of surgery and surgeons has also evolved because surgeons not only perform the initial curative lung cancer resection but they also accompany and follow-up patients from pre-operative rehabilitation, to treatment for recurrences.
View Article and Find Full Text PDF